A Phase 1 interventional study of SHR8554 Injection in Moderate to Severe Postoperative Pain, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-24.
Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 248 studies in Pain, Postoperative with a site in China — 78 open to participants now, 80 under way, 3 of them phase 3. Pain, Postoperative · China.
Among the 248 studies in Pain, Postoperative with a site in China, this one is the 201st largest by enrollment of the 205 interventional ones that give a count, is one of 29 that started in 2022, is one of 6 in phase 1, and was the 197th registered.
5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.
Browse Pain, Postoperative studies →78 of the 248 studies in Pain, Postoperative with a site in China are open now. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18–80
First Affiliated Hospital of Chongqing Medical University · Sites in China
Ages 18–90
Huazhong University of Science and Technology · Sites in China
Ages 18–80
Shanghai 6th People's Hospital · Sites in China
Ages 18–60
Tianjin First Central Hospital · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
248 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 21 · Phase 3 13 · Phase 4 67
First in 2004; this study’s year is marked. 29 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 75 across 4,835 interventional studies indexed under Pain, Postoperative.
Median enrollment 132 across the 205 interventional studies, 350 across the 43 observational. Of the 121 that completed or were terminated, 6 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 248 have an industry lead sponsor. The 10 most frequent:
Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.
Jiangsu HengRui Medicine Co., Ltd. has 8 studies filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
21 of the studies in Pain, Postoperative with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07331441Jun ZhangExternal Oblique Intercostal Plane Block for Postoperative Analgesia After Major Upper Abdominal Surgery | 2026-11-25 |
| NCT07412223Xiangya Hospital of Central South UniversityEffect of Tegileridine on Postoperative Bowel Function Recovery in Abdominal Surgery | 2026-12-01 |
| NCT07653932Tongji HospitalPerioperative Quantitative Sensory Testing and Incision Pain Mapping in Thoracic Surgery | 2026-12-31 |
| NCT07519109CSPC Ouyi Pharmaceutical Co., Ltd.Study Evaluating the Safety, Efficacy and Pharmacokinetics of SYH9089 Injection in Patients Undergoing Abdominal Surgery. | 2026-12-31 |
| NCT06320041The Fourth Affiliated Hospital of Zhejiang University School of MedicineEfficacy and Safety of Oliceridine for Moderate to Severe Acute Pain After Orthopedic Surgery | 2026-12-31 |
Add all 21 to your calendar (.ics) → With an account.
Among the 248 studies in Pain, Postoperative with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study is being conducted to evaluate the safety and pharmacokinetic characteristics of SHR8554 injection in subjects with renal insufficiency and healthy subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: SHR8554 Injection
Drug: SHR8554 Injection
SHR8554 injection.
Maximum observed concentration of SHR8554 (Cmax).
Time frame: 0 hour to 48 hours after administration.
Area under the serum concentration time curve (AUC) of SHR8554.
Time frame: 0 hour to 48 hours after administration.
Half-life (t1/2) of SHR8554.
Time frame: 0 hour to 48 hours after administration.
Clearance (CL) of SHR8554.
Time frame: 0 hour to 48 hours after administration.
Volume of distribution (Vz) of SHR8554.
Time frame: 0 hour to 48 hours after administration.
Cumulative excretion (Ae) of SHR8554.
Time frame: 0 hour to 48 hours after administration.
Urinary excretion fraction (fe) of SHR8554.
Time frame: 0 hour to 48 hours after administration.
Renal clearance (CLr) of SHR8554.
Time frame: 0 hour to 48 hours after administration.
Plasma protein binding rate of SHR8554 in patients with renal insufficiency.
Time frame: 0 hour to 48 hours after administration.
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Sep 2022 to primary completion in Apr 2023, 6 months.
Of 83 phase 1 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 27. This study's 6 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: SHR8554
Jiangsu HengRui Medicine Co., Ltd. →